944549-53-5

Basic information

• Product Name: 3-{4-[3-chloro-4-(3-fluorobenzyloxy)phenylamino]quinazolin-6-yl}benzaldehyde
• Synonyms: 3-{4-[3-chloro-4-(3-fluorobenzyloxy)phenylamino]quinazolin-6-yl}benzaldehyde
• CAS NO: 944549-53-5
• Molecular Weight: 483.929
• Mol File: 944549-53-5.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: 3-{4-[3-chloro-4-(3-fluorobenzyloxy)phenylamino]quinazolin-6-yl}benzaldehyde(CAS DataBase Reference)
• NIST Chemistry Reference: 3-{4-[3-chloro-4-(3-fluorobenzyloxy)phenylamino]quinazolin-6-yl}benzaldehyde(944549-53-5)
• EPA Substance Registry System: 3-{4-[3-chloro-4-(3-fluorobenzyloxy)phenylamino]quinazolin-6-yl}benzaldehyde(944549-53-5)

Safety Data

• Hazardous Substances Data: 944549-53-5(Hazardous Substances Data)

Upstream product

• 202197-26-0 3-chloro-4-(3-fluorobenzyloxy)aniline 
• 5326-47-6 2-amino-5-iodobenzoic acid 
• 456-47-3 3-fluoro-benzenemethanol 
• 350-30-1 3-chloro-4-fluoronitrobenzene 
• 98556-31-1 4-chloro-6-iodoquinazoline 
• 16064-08-7 6-iodo-1H-quinazolin-4-one 
• 443882-99-3 3-chloro-4-(3-fluorobenzyloxy)nitrobenzene 
• 87199-16-4 3-Formylphenylboronic acid 
• 231278-20-9 N-(3-chloro-4-(3-fluorobenzyloxy)phenyl)-6-iodoquinazolin-4-amine 
• 944549-41-1 N-[3-chloro-4-[(3-fluorobenzyl)oxy]phenyl]-6-bromo-quinazolin-4-amine 

Downstream Products

• 944549-43-3 4-[3-chloro-4-(3-fluorobenzyloxy)-phenylamino]-6-(3-hydroxymethyl-phenyl)-quinazoline 
• 1257665-57-8 3-[3-{4-(3-chloro-4-(3-fluorobenzyloxy)phenylamino)quinazolin-6-yl}phenyl]acrylic acid tert-butyl ester 

Relevant articles and documents

Novel chimeric histone deacetylase inhibitors: A series of lapatinib hybrides as potent inhibitors of epidermal growth factor receptor (EGFR), human epidermal growth factor receptor 2 (HER2), and histone deacetylase activity

Reversible lysine-specific acetylation has been described as an important posttranslational modification, regulating chromatin structure and transcriptional activity in the case of core histone proteins. Histone deacetylases (HDAC) are considered as a promising target for anticancer drug development, with 2a as pan-HDAC inhibitor approved for cutanous T-cell lymphoma therapy and several other HDAC inhibitors currently in preclinical and clinical development. Protein kinases are a well-established target for cancer therapy with the EGFR/HER2 inhibitor 5 approved for treatment of advanced, HER2 positive breast cancer as a prominent example. In the present report, we present a novel strategy for cancer drug development by combination of EGFR/HER2 kinase and HDAC inhibitory activity in one molecule. By combining the structural features of 5 with an (E)-3-(aryl)-N-hydroxyacrylamide motif known from HDAC inhibitors like 1 or 3, we obtained selective inhibitors for both targets with potent cellular activity (target inhibition and cytotoxicity) of selected compounds 6a and 6c. By combining two distinct pharmacologically properties in one molecule, we postulate a broader activity spectrum and less likelihood of drug resistance in cancer patients.

QUINAZOLINE DERIVATIVES,PREPARATION METHODS AND USES THEREOF

The present invention has disclosed a compound of formula I and a pharmaceutically acceptable salt or a solvate thereof, wherein the substituents are as defined in the description. The invention has also disclosed a method for preparing the compound of formula I, the pharmaceutical compositions comprising the same and their uses in the preparation of an anti- tumor medicament.